Moreover, the combination of SHP2 and FAK inhibitors resulted in a stronger reduction of AKT signaling in CRC cells, indicating that the role of FAK inhibitor as a sensitizer on SHP2 inhibitor depends at least partly on the blockage of AKT pathway reactivation induced by SHP2 inhibition. The gene discussed is AKT1; the disease is colorectal carcinoma.